Read More Pharma Industry News Why argenx is buying Forte Biosciences before FB102 enters its bigger proof stage argenx agrees to buy Forte Biosciences for $2.2 billion. Read how FB102 could reduce Vyvgart concentration risk and reshape ARGX’s autoimmune strategy. byVenkateshJuly 31, 2026